The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.

CHEERS TO 30 YEARS!

Join us Friday, October 27th at 7:00pm for a celebration that's been 30 years in the making! 

Learn More!

Download the Flyer!

HONORING THE MEMORY OF DR. STEVEN GRUNBERG

As we look back at the milestones in NNECOS’ 30-year history, we also remember the people. We honor the memory of friend and long-time NNECOS leader, Dr. Steven Grunberg.

Looking Back!

Enjoy this wonderful interview with 3 of NNECOS' founding members!



NNECOS LUNCHTIME WEBINARS

lunchtime Webinars

Check out these complimentary Lunchtime Webinars:

  • Oct 27 - Psychological Impact of Genetic Testing Panel
  • Nov 3 - Follicular Lymphoma: Disease Overview and the Unmet Need
  • Nov 10 - Compassion Fatigue
  • Nov 18 - Regulatory & Legislative Update

CANCER COMMUNITY SUPPORT


NNECOS Helps

Please read this special message to our community.

Latest FDA Approvals And Drug-Related Updates

Latest FDA Approvals

  • Oct 15 - FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer
  • Oct 13 - FDA approves pembrolizumab combination for the first-line treatment of cervical cancer
  • Oct 12 - FDA approves abemaciclib with endocrine therapy for early breast cancer
  • Oct 1 - FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell precursor acute lymphoblastic leukemia
  • Sep 22 - FDA approves ruxolitinib for chronic graft-versus-host disease
  • Sep 20  - FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer
  • Sep 17 - FDA approves cabozantinib for differentiated thyroid cancer 
  • Sep 15 - FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations 
  • Sep 14 - FDA grants accelerated approval to zanubrutinib for marginal zone lymphoma 

Package/Label Updates

Code Updates
  • Oct 1 - J-code J9247 for Pepaxto┬« (melphalan flufenamide) injection, 1mg
  • Oct 1 - J-Code J1448 for COSELA™ (trilaciclib)

Other Updates

Oct 7 - FDA recognizes Memorial Sloan-Kettering database of molecular tumor marker information

New Job Posted - NNECOS Classifieds

  • Northern Light Health Eastern Maine Medical Center - board-certified/board eligible hematologist/oncologist
  • UVM Medical Center - Assistant/Associate Professor/Professor, Clinical Scholar Pathway, Hematology/Oncology
  • New England Cancer Specialists - multiple positions

ASCO Twitter Feeds

SOCIAL MEDIA

 

Upcoming events

10 Nov 2021 12:15 PM • Online webinar
18 Nov 2021 12:15 PM • Online webinar
31 Dec 2021 • Maine, New Hampshire, Vermont

SHARE WITH NNECOS


Do you have an idea, suggestion, or other feedback you'd like to share? Comment, concern or compliment? Reach out and

Share with NNECOS.

We'd love to hear from you! 

Thank You Corporate Members!


NNECOS News

NNECOS News

Group Practice Members

Because your entire team benefits
from being a part of NNECOS!

COVID SURVEY AND RESOURCES

ASCO Survey on COVID in Oncology Registry

The aim is to help the cancer community learn more about the patterns of symptoms & severity of COVID among patients with cancer, as well as the impact on delivery of cancer care & patient outcomes. Periodic reports will deliver real-time information to the oncology community.

ASCO COVID Resource Page

COVID Info & Resources including a Fact Sheet on EUA of BAmlanivimab

State Advocacy


Special thanks to our 2021 Diamond & Platinum Corporate Members!

  
  
  
  
  

Platinum Members

 

  
  
  
    
    
    
    

View the complete list of supporters.

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software